Global Human Microbiome Market Size & Trends Report Segmented by Product (Prebiotics, Probiotics, Drugs, & Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Bio-Therapeutic), End-user & Regional Forecasts to 2030
The human microbiome market is projected to grow at a CAGR of 31% over the forecast period. Major factors driving growth include advancement in microbiome sequencing technology, increasing number of biotech startups exploring microbiome therapies, growing collaboration between organizations and academia in microbiome industry, growing investment in microbiome research and therapeutics by public and private organizations, rising incidence of chronic and lifestyle-related diseases, and shift towards preventive and personalized medicines. To learn more about the research report, download a sample report.
Report Overview
The human microbiome refers to the diverse community of microorganisms such as bacteria, viruses, fungi, archaea, eukaryotes, and other microbes that live in and on the human body. These microbes are found in various areas, including the gut, skin, mouth, respiratory system, and other mucosal surfaces, where they play a vital role in maintaining health and supporting essential bodily functions. Initially, it was believed that the microbiome contained approximately 100 times more genes than the human genome, but further research has adjusted this estimate to about ten times more. While these microbes are typically not harmful, they are crucial for our well-being. For example, they produce vitamins that our bodies cannot synthesize, help break down food to extract necessary nutrients, train our immune systems to identify harmful pathogens, and even generate anti-inflammatory compounds that combat disease-causing microbes. 
To learn more about the research report, download a sample report.
Advancements in microbiome research and technologies driving market growth
The rapid pace of scientific advancements in microbiome research is one of the most significant drivers of the human microbiome market. The increasing understanding of the microbiome's role in human health particularly its influence on immunity, metabolism, mental health, and disease is catalyzing innovation in microbiome-based therapies, diagnostics, and products. More than 100 trillion microorganisms live in the human body, and their interactions with host cells are complex. Ongoing research is revealing how the microbiome can influence disease onset, progression, and treatment outcomes, spurring the development of new therapeutic strategies, personalized medicine, and consumer products like probiotics and prebiotics. As technology improves and more studies are conducted, the potential for microbiome-based solutions to transform disease prevention, treatment, and overall well-being continues to grow.
To learn more about the research report, download a sample report.
Increasing investments in microbiome-based therapies and diagnostics by pharmaceutical companies and biotechnology firms propel market growth
Recent advancements in sequencing technologies and synthetic biology have confirmed the connection between the microbiome and various diseases, leading to a surge in research funding and investment in microbiome-related therapeutics, diagnostics, and products. Investments in microbiome-focused startups is expected to rise, as venture capitalists and pharma companies aim to capitalize on the promising potential of microbiome-based therapeutics and diagnostics. For example, venture capital investments in microbiome startups reached record levels, reflecting growing confidence in the sector's future. This influx of capital is driving the commercialization of microbiome-based therapeutics, including FMT, microbiome-modulating drugs, and innovative probiotics, while also expanding clinical trials on the microbiome's impact on various diseases. As per the article published by strategy& (part of PwC group) there were 43 VC-backed deals valued at $321 million in 2022. North America and Europe remain the leading regions for microbiome funding, though investment is also growing in the Asia-Pacific region.
Key Constraints/Challenges
The market is confronted with challenges such as scientific and regulatory barriers, as well as a lack of standardization due to the use of numerous microbial strains that are difficult to distinguish. Additionally, there is a limited public understanding and a need for education to highlight the broad health benefits offered by products containing these bacteria.
Competitive Landscape Analysis
The global human microbiome market is marked by the presence of established and emerging market players such as OpenBiome; Bayers AG; Danone; Nestle, Seres Therapeutics Inc.; Ferring Pharmaceuticals; Enterome SA; Finch Therapeutics Group, Inc.; Biomebank, Microbiotica; Seeds Health, Inc.; Synlogic; and Vedanta Bioscience, Inc. among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and investments.
Report Scope
| Report Scope | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| Growth Rate | 31% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Product, Disease, Type, and End-user |
| Regional Scope |
|
| Key Companies Mapped | OpenBiome; Bayers AG; Danone; Nestle; Seres Therapeutics Inc.; Ferring Pharmaceuticals; Enterome SA; Finch Therapeutics Group, Inc.; Biomebank; Microbiotica; Seeds Health, Inc.; Synlogic; and Vedanta Bioscience, Inc. |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Market Segmentation
This report by Medi-Tech Insights provides the size of the global human microbiome market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, disease, type, and end-user.
- Market Size & Forecast (2023-2030), By Product, USD Million
- Drugs
- Prebiotics
- Probiotics
- Synbiotics
- Market Size & Forecast (2023-2030), By Disease, USD Million
- Infectious Diseases
- Gastrointestinal Diseases
- Endocrine and Metabolic Disorders
- Other Diseases
- Market Size & Forecast (2023-2030), By Type, USD Million
- Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT)
- Live Bio therapeutic Products
- Other Types
- Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals & Clinics
- Long-Term Care Facilities
- Others
- Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
- North America
Key Strategic Questions Addressed
- What is the market size & forecast of the human microbiome market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the human microbiome market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction​
- Market Scope​
- Market Definition​
- Segments Covered​
- Regional Segmentation​
- Research Timeframe​
- Currency Considered​
- Study Limitations​
- Stakeholders​
- List of Abbreviations​
- Key Conferences and Events (2025-2026)​
- Research Methodology​
- Secondary Research​
- Primary Research​
- Market Estimation​
- Bottom-Up Approach​
- Top-Down Approach​
- Market Forecasting​
- Executive Summary
- Human Microbiome Market Snapshot (2025-2030)​
- Segment Overview​
- Regional Snapshot​
- Competitive Insights ​
- Market Overview
- Market Dynamics
- Drivers
- Advancements in microbiome sequencing technology
- Increasing number of biotech startups exploring microbiome therapies
- Growing investments in microbiome research and therapeutics by public and private organizations
- Rising incidence of chronic and lifestyle-related diseases
- Shift towards preventive and personalized medicines
- Restraints​
- Complexity of the microbiome
- Limited public understanding for these bacteria-containing products
- Stringent regulatory hurdles for new technologies and therapies
- Opportunities​
- Growing application of microbiome science in regenerative medicine and tissue engineering
- Adoption of AI and big data in microbiome research
- Opportunities in microbiome-based cosmetic products
- Key Market Trends​
- Leveraging microbiome research in cancer treatment
- Increased investment and funding from Venture Capitals and pharmaceuticals companies
- Growing focus of microbiome therapies in rare and chronic diseases
- Unmet Market Needs​
- Industry Speaks​
- Global Human Microbiome Market Size & Forecast (2023-2030), By Product, USD Million
- Introduction​
- Drugs
- Prebiotics
- Probiotics
- Synbiotics
- Global Human Microbiome Market Size & Forecast (2023-2030), By Disease, USD Million
- Introduction​
- Infectious Diseases
- Gastrointestinal Diseases
- Endocrine and Metabolic Disorders
- Other Diseases
- Global Human Microbiome Market Size & Forecast (2023-2030), By Type, USD Million
- Introduction​
- Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT)
- Live Bio therapeutic Products
- Other Types
- Global Human Microbiome Market Size & Forecast (2023-2030), By End-user, USD Million
- Introduction​
- Hospitals & Clinics
- Long-Term Care Facilities
- Others
- Global Human Microbiome Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction​
- North America Human Microbiome Market Size & Forecast (2023-2030), By Country, USD Million​
- US​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Canada​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- US​
- Europe Human Microbiome Market Size & Forecast (2023-2030), By Country, USD Million​
- UK ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Germany ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Italy ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Spain ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Rest of Europe ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- UK ​
- Asia Pacific (APAC) Human Microbiome Market Size & Forecast (2023-2030), By Country, USD Million​
- China ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Japan ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- India ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Rest of Asia Pacific ​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- China ​
- Latin America (LATAM) Human Microbiome Market Size & Forecast (2023-2030), USD Million​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Middle East & Africa (MEA) Human Microbiome Market Size & Forecast (2023-2030), USD Million​
- Market Size & Forecast, By Product (USD Million)​
- Market Size & Forecast, By Disease (USD Million)
- Market Size & Forecast, By Type (USD Million)​
- Market Size & Forecast, By End-user (USD Million)​​
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2024)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles* (Business Overview, Financial Performance**, Products Offered, Recent Developments)
- Nestle
- Ferring Pharmaceuticals
- OpenBiome
- Bayers AG
- Danone
- Seres Therapeutics Inc.
- Enterome SA
- Finch Therapeutics Group, Inc.
- Vedanta Bioscience
- Microbiotica
- Other Prominent Players
  Note: *Indicative list
  **For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals & Clinics, Long-term Care Facilities and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
